Change-a Multi-center Chronic Thromboembolic Pulmonary Hypertension （CTEPH） Database in China
NCT ID: NCT05311072
Last Updated: 2024-01-23
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
1500 participants
OBSERVATIONAL
2015-10-01
2027-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Pulmonary Hypertension Observational Study
NCT05958901
CHASE Registry of Patients With Pulmonary Hypertension Receiving Targeted Therapy
NCT06135909
Hypertension Registry of "Hypertension Prevention and Control Initiative in China"
NCT04289701
A Study Investigating Routine Practice of Chronic Thromboembolic Pulmonary Hypertension Management in EMEA Countries
NCT02637050
Blood Pressure Follow-up Study in Two Chinese Cohorts(C-BPCS)
NCT02734472
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
PEA cohort
patients with CTEPH receiving PEA
pulmonary endarterectomy or balloon pulmonary angioplasty
A multidisciplinary team make the final treatments for patients with CTEPH depending on their disease and preferences.
BPA cohort
patients with CTEPH receiving BPA
pulmonary endarterectomy or balloon pulmonary angioplasty
A multidisciplinary team make the final treatments for patients with CTEPH depending on their disease and preferences.
Pulmonary arterial hypertension (PAH)-specific medication
CTEPH patients without PEA or BPA, treatment with any PAH-specific medication, i.e. endothelin receptor antagonists, phosphodiesterase type 5 inhibitors, soluble guanylate cyclase stimulators, drugs acting on the prostanoid pathway and prostaglandin I2 receptor agonists
pulmonary endarterectomy or balloon pulmonary angioplasty
A multidisciplinary team make the final treatments for patients with CTEPH depending on their disease and preferences.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
pulmonary endarterectomy or balloon pulmonary angioplasty
A multidisciplinary team make the final treatments for patients with CTEPH depending on their disease and preferences.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Patients must be willing to provide informed consent
3. Patients must meet the following criteria for CTEPH:
a mean pulmonary artery pressures (mPAP) ≥20 mmHg combined with a pulmonary vascular resistance (PVR) ≥ 3 WU and pulmonary arterial wedge pressure (PAWP)≤ 15 mmHg documented at right heart catheterization with radiographic evidence of organized thrombi involving the pulmonary arteries after 3 months of effective anticoagulation.
Exclusion Criteria
2. Participation in a therapeutic clinical trial with an unknown drug;
3. Withdrawal or lack of informed consent.
14 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
China-Japan Friendship Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Zhenguo Zhai,MD,PhD
Principal Investigator
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
China-Japan Frendship hospital
Beijing, , China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
References
Explore related publications, articles, or registry entries linked to this study.
Zhang S, Li Y, Yang Y, Gong S, Yang Z, Hong C, Cui X, Wan J, Ji Y, Chen H, Zhu L, Li C, Cheng Z, Zhang Y, Wang Q, Luo Q, Guo L, Ma G, Han B, Liu Z, Xiong C, Wang L, Ji Q, Li F, Wang S, Zhang Z, Zhang Y, Wang D, Gao Q, Huang Q, Xie W, Zhai Z, Wang C. The management pattern and outcomes of chronic thromboembolic pulmonary hypertension: rationale and design for a Chinese real-world study. BMC Pulm Med. 2024 Jun 3;24(1):265. doi: 10.1186/s12890-024-03042-5.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Change-CTEPH
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.